Biweekly Docetaxel and S-1 Combination Chemotherapy as First-line Treatment for Elderly Patients with Advanced Gastric Cancer

被引：1
|
作者：
Kunisaki, Chikara [1 ]
Takahashi, Masazumi [2 ]
Ono, Hidetaka A. [1 ]
Hasegawa, Shinichi [1 ]
Tsuchida, Kazuhito [1 ]
Oshima, Takashi [1 ]
Ota, Mitsuyoshi [1 ]
Fukushima, Tadao [1 ]
Tokuhisa, Motohiko [3 ]
Izumisawa, Yusuice [3 ]
Takagawa, Ryo [3 ]
Kimura, Jun [3 ]
Kosaka, Takashi [3 ]
Makino, Hirochika [3 ]
Akiyama, Hirotoshi [3 ]
Endo, Itaru [3 ]
机构：
[1] Yokohama City Univ, Dept Surg, Gastroenterol Ctr, Minami Ku, Yokohama, Kanagawa 2320024, Japan
[2] Yokohama Municipal Hosp, Dept Surg, Hodogaya Ku, Yokohama, Kanagawa, Japan
[3] Yokohama City Univ, Dept Surg Gastroenterol, Kanazawa Ku, Yokohama, Kanagawa 2320024, Japan
来源：
ANTICANCER RESEARCH | 2013年 / 33卷 / 02期
关键词：
Advanced gastric cancer; chemotherapy; docetaxel; elderly; S-1; ADVANCED ESOPHAGOGASTRIC CANCER; PHASE-III TRIAL; PLUS CISPLATIN; LEUCOVORIN; FLUOROURACIL; THERAPY; ADENOCARCINOMA; OXALIPLATIN; MULTICENTER; I/II;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background/Aim: This study assessed the toxicity and activity of biweekly docetaxel and S-1 combination therapy in elderly patients with advanced gastric cancer. Patients and Methods: One-hundred and thirteen patients were enrolled: 35 were 75 years old or more. The objective response rate, toxicity, progression-free survival (PFS), and overall survival (OS) were compared. Results: Dose reduction was significantly frequent in the elderly group (24135 versus 25178, p<0.001). The overall response rate was 54.9%. Out of these, 18 (15.9%) underwent gastrectomy (13 R0 gastrectomy). The median OS was 17.3 months and the median PFS was 8.0 months. Neutropenia was the most frequently observed hematological toxicity at grade 3 and 4 (34.5%), followed by leukopenia (24.8%). Most non-hematological toxicities were of grade 1 or 2. There were no significant differences in overall response rate, median OS, median PFS, or toxicities between the two groups. Conclusion: This combination offers favourable survival benefits with controllable tolerance for therapy of AGC in the elderly.
引用
收藏
页码：697 / 704
页数：8
相关论文
共 50 条
  • [21] Docetaxel/S-1 Versus Docetaxel/Capecitabine as First-Line Treatment for Advanced Breast Cancer
    Li, Jinyu
    You, Junhao
    Si, Wen
    Zhu, Yanyun
    Chen, Yi
    Yang, Bo
    Han, Chun
    Linghu, Ruixia
    Zhang, Xingyang
    Jiao, Shunchang
    Yang, Junlan
    [J]. MEDICINE, 2015, 94 (41)
  • [22] Phase II study of S-1 plus docetaxel as first-line treatment for elderly patients with advanced gastric cancer (OGSG0902).
    Matsuyama, Jin
    Imamura, Hiroshi
    Kawabata, Ryohei
    Kawase, Tomono
    Okada, Kazuyuki
    Nishikawa, Kazuhiro
    Kurokawa, Yukinori
    Fujitani, Kazumasa
    Shimokawa, Toshio
    Satoh, Taroh
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (04)
  • [23] A phase II study of S-1 and irinotecan combination chemotherapy in patients with advanced gastric cancer as a first-line therapy
    Ryoo, B. Y.
    Kang, H. J.
    Yang, S. H.
    Cho, S. H.
    Oh, S. J.
    Lee, M. H.
    Song, E. K.
    Chung, H. C.
    [J]. EJC SUPPLEMENTS, 2007, 5 (04): : 274 - 274
  • [24] Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer
    Kosaka, Takashi
    Akiyama, Hirotoshi
    Makino, Hirochika
    Takagawa, Ryo
    Kimura, Jun
    Ono, Hidetaka
    Kunisaki, Chikara
    Endo, Itaru
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 73 (02) : 281 - 285
  • [25] Preoperative S-1 and docetaxel combination chemotherapy in patients with locally advanced gastric cancer
    Takashi Kosaka
    Hirotoshi Akiyama
    Hirochika Makino
    Ryo Takagawa
    Jun Kimura
    Hidetaka Ono
    Chikara Kunisaki
    Itaru Endo
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 73 : 281 - 285
  • [26] Compliance with biweekly SOX combination chemotherapy versus triweekly SOX as a first-line therapy for elderly patients with advanced gastric cancer.
    Zhang, Shu
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [27] Survival Outcomes Following Combination of First-Line Platinum-Based Chemotherapy with S-1 in Patients with Advanced Gastric Cancer
    Koumarianou, Anna
    Ntavatzikos, Anastasios
    Vallilas, Christos
    Kampoli, Katerina
    Kakoseou, Zoi
    Karamouzis, Michalis, V
    [J]. CANCERS, 2020, 12 (12) : 1 - 12
  • [28] Three-week combination chemotherapy with S-1 and cisplatin as first-line treatment in patients with advanced gastric cancer: a retrospective study with 159 patients
    Koo, Dong Hoe
    Ryu, Min-Hee
    Ryoo, Baek-Yeol
    Lee, Sung-Sook
    Moon, Jung-Hwa
    Chang, Heung-Moon
    Lee, Jae-Lyun
    Kim, Tae Won
    Kang, Yoon-Koo
    [J]. GASTRIC CANCER, 2012, 15 (03) : 305 - 312
  • [29] A phase II study of S-1 and oxaliplatin (SOx) combination chemotherapy as a first-line therapy for patients with advanced gastric cancer
    Sung Yong Oh
    Hyuk-Chan Kwon
    Sang-Ho Jeong
    Young-Tae Joo
    Young-Joon Lee
    Su hee Cho
    Myoung Hee Kang
    Se-il Go
    Gyeong-won Lee
    Hoon gu Kim
    Jung Hun Kang
    [J]. Investigational New Drugs, 2012, 30 : 350 - 356
  • [30] Phase II study of S-1 in combination with paclitaxel as a first-line treatment for patients with advanced/recurrent gastric cancer
    Toh, U.
    Yamana, H.
    Koufuji, K.
    Mine, T.
    Aoyagi, K.
    Miyagi, M.
    Imaizumi, T.
    Shirouzu, K.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345